Business Description
Nutra Pharma Corp
NAICS : 325411
SIC : 2834
ISIN : US67060U2087
Total Employee Number:
7Description
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -34.04 | |||||
Debt-to-Equity | -0.58 | |||||
Debt-to-EBITDA | -2.51 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -252.64 | |||||
Beneish M-Score | -10.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.02 | |||||
Quick Ratio | 0.02 | |||||
Days Inventory | 48.35 | |||||
Days Sales Outstanding | 67.08 | |||||
Days Payable | 1969.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -205.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.54 | |||||
Operating Margin % | -631.66 | |||||
Net Margin % | -2093.44 | |||||
EBITDA Margin % | -1898.84 | |||||
FCF Margin % | -405.4 | |||||
OCF Margin % | -405.41 | |||||
ROA % | -798.76 | |||||
ROIC % | -14.23 | |||||
3-Year ROIIC % | 25.49 | |||||
ROC (Joel Greenblatt) % | -12500 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -2.64 | |||||
EV-to-Revenue | 50.42 | |||||
EV-to-FCF | -12.44 | |||||
Earnings Yield (Greenblatt) % | -38.02 | |||||
FCF Yield % | -146.65 |
GF Valueâ„¢
Nutra Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nutra Pharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-09-16 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-19 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-29 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-05-20 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2026-04-06 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2026-03-25 | 0.00 (+0.00%) | ||
| First quarter earnings results for 2025 | 2026-03-11 | 0.00 (+0.00%) | ||
| Annual report for 2024 | 2026-02-17 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2026-01-02 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2025-12-23 | 0.00 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers